Biofrontera's earnings have been declining at an average annual rate of -1.2%, while the Pharmaceuticals industry saw earnings growing at 3.4% annually. Revenues have been declining at an average rate of 13.8% per year.
Key information
-1.25%
Earnings growth rate
0.69%
EPS growth rate
Pharmaceuticals Industry Growth
14.12%
Revenue growth rate
-13.81%
Return on equity
-39.05%
Net Margin
-48.98%
Next Earnings Update
30 Sep 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Biofrontera makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
LSE:0DOL Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Mar 26
14
-7
10
2
31 Dec 25
13
-7
10
2
30 Sep 25
23
-2
14
4
31 Mar 25
12
4
9
1
31 Dec 24
12
1
10
2
30 Sep 24
18
0
12
6
30 Jun 24
22
-3
11
8
31 Mar 24
30
0
12
8
31 Dec 23
32
0
13
8
30 Sep 23
29
-9
13
8
30 Jun 23
28
-11
13
8
31 Mar 23
25
-20
13
7
31 Dec 22
26
-44
12
7
30 Sep 22
32
11
18
7
30 Jun 22
31
10
24
7
31 Mar 22
30
15
29
7
31 Dec 21
29
38
34
7
30 Sep 21
28
-16
30
6
30 Jun 21
27
-16
29
5
31 Mar 21
29
-12
26
5
31 Dec 20
30
-13
28
5
30 Sep 20
33
-17
33
5
30 Jun 20
33
-22
37
5
31 Mar 20
31
-10
45
5
31 Dec 19
31
-7
44
5
30 Sep 19
26
1
44
4
30 Jun 19
26
8
40
5
31 Mar 19
23
-8
33
5
31 Dec 18
21
-9
31
4
30 Sep 18
19
-14
24
4
30 Jun 18
16
-15
22
4
31 Mar 18
14
-16
21
4
31 Dec 17
12
-16
20
4
30 Sep 17
11
-18
21
5
30 Jun 17
9
-16
17
5
31 Mar 17
8
-14
14
5
31 Dec 16
6
-11
12
5
30 Sep 16
4
-9
9
4
30 Jun 16
4
-7
8
4
31 Mar 16
4
-9
7
6
31 Dec 15
4
-11
7
6
30 Sep 15
4
-12
7
7
30 Jun 15
3
-13
7
7
Quality Earnings: 0DOL is currently unprofitable.
Growing Profit Margin: 0DOL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0DOL is unprofitable, and losses have increased over the past 5 years at a rate of 1.2% per year.
Accelerating Growth: Unable to compare 0DOL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0DOL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (33.7%).
Return on Equity
High ROE: 0DOL has a negative Return on Equity (-39.05%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/06/21 21:24
End of Day Share Price
2026/05/28 00:00
Earnings
2026/03/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Biofrontera AG is covered by 6 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.